Logo smallSearch
Dr. Marek Derkacz, MBA

Semaglutide - an extremely important new ally in the fight for the health of Poles

MedExpress Team

Dr n. med. Marek Derkacz

Published July 10, 2023 07:03

Semaglutide - an extremely important new ally in the fight for the health of Poles - Header image
Fot. arch. red.
Analyzing my own experience over the past two years, I wanted to provide you with a thorough analysis of the health benefits and potential total economic gains from the wider use of semaglutide, an innovative drug for the treatment of type 2 diabetes and obesity, in the context of the impact on the Polish health care system.

My attention - both as a practicing physician, diabetologist and endocrinologist, as well as a specialist in economics and health care - has been drawn for several months to the need to expand the reimbursement indications for semaglutide. Of course, this is all with the most important condition in mind - the health benefits for patients, as well as for the health care system. If someone is still wondering whether it is worth it, to gain conviction and get rid of doubts, just consider the beneficial effect of semaglutide on the overall health of Poles, including the reduction in the incidence of diseases related to obesity and type 2 diabetes. As for the use of the drug, my experience of more than two years with this still all time considered new drug is extremely positive.

Type 2 diabetes and obesity are chronic diseases that often coexist with each other, but also represent a growing health problem worldwide, including Poland, every year due to the increase in the number of cases. The negative consequences of these diseases are well known. Among the most common are: increased risk of cardiovascular disease, including strokes, kidney disease, neuropathy, as well as increased risk of developing certain cancers. All of us, doctors and even more so patients, are aware of the lower quality of life and shortened length of life in people suffering from obesity and type 2 diabetes, all of which translates into significant and ever-increasing costs to the health care system worldwide and to our society as a whole.

In this context, semaglutide (prep. Ozempic - used subcutaneously once a week or orally once a day - Rybelsus), dulaglutide (prep. Trulicity administered subcutaneously every 7 days) and other drugs that are, like the aforementioned GLP-1 analogs, are extremely promising tools in the fight against these serious health problems facing us as a society....

Content locked

To gain access to the complete English section of the, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also

Prof. Wiesław Jędrzejczak

Shot down in flight

July 20, 2022
Walenty Zajdel

Pharmacies on duty

Sept. 12, 2022
Walenty Zajdel

World Patient Safety Day

Sept. 19, 2022
Leszek Borkowski
Leszek Borkowski

How to help demographics in Poland

Sept. 7, 2023
Leszek Borkowski
Leszek Borkowski

Głosić dobre informacje przed i po wyborach

Sept. 26, 2023
FeatureMałgorzata Solecka

The record is not the issue here

Jan. 29, 2024
FeatureMałgorzata Solecka

Two words are enough for a wise head

Feb. 19, 2024